Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Significant Drop in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a significant drop in short interest in June. As of June 15th, there was short interest totaling 137 shares, a drop of 55.8% from the May 31st total of 310 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 3,304 shares, the days-to-cover ratio is presently 0.0 days.

Enzon Pharmaceuticals Stock Performance

Shares of Enzon Pharmaceuticals stock opened at $5.11 on Monday. Enzon Pharmaceuticals has a 12 month low of $1.50 and a 12 month high of $12.99. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $3.78 million, a PE ratio of -0.75 and a beta of -0.06. The stock’s fifty day simple moving average is $5.85 and its 200 day simple moving average is $5.70.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.